Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
G&E Herbal Biotechnology Co., Ltd. (4911.TWO)
Tainan City, CN
G&E Herbal Biotechnology Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the innovation and commercialization of advanced botanical extraction technologies and the products derived from them. Its diverse portfolio features a range of botanical anti-aging cosmetic items, including facial foam cleansers, cleansing essences, toners, lightening lotions, essential oils, and moisturizing serums and creams, along with specialized products like the SR-100 botanical essence and bromelain illuminating cleansing mousse. The company also manufactures capsules designed as hepato-protective agents. In the realm of wellness, G&E offers a selection of botanical healthcare products such as ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules, as well as various products catering to adults. Looking to its future developments, the company is actively pursuing new treatments, including Solarise injection for gynecologic, head, and neck cancers; Apocin capsules intended for non-small cell lung cancer; and SR-T100 Gel, which targets common and genital warts. Beyond its own product lines, G&E Herbal Biotechnology is involved in creating manufacturing technologies for a wide array of dietary supplements and provides expert technical advisory services to other biotechnology organizations. The company was founded in 2002 and is headquartered in Tainan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31% | +0.63% | -8.10% | -11.44% | -33.72% | -25.99% | -36.14% | -54.11% | +36.15% | -71.38% | -31.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+24.1% ★ Q1'26: -59.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+26.0% Q1'26: -62.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.7% Q1'26: -20.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+49.3% ★ Q1'26: +16.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+26.5% ★ Q1'26: +4.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.1% Q1'26: +8.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.04× ★ Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
|---|---|
| Revenue |
25.71M
est: 32.00M (-19.6%)
|
| EBITDA |
-16.18M
est: 4.56M (-454.9%)
|
| EBIT |
-18.83M
est: -1.49M (-1,165.2%)
|
| Net Income |
5.72M
|
| SGA |
12.84M
est: 12.29M (+4.5%)
|
| EPS |
0.10
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xuan Xuan Lin | Marketing Director | 5M | female |
| Kou-Wha Kou | Chief Executive Officer of R&D Department, CEO & Chairman | 5M | male |
| Bing Yuan Chen | Production Manager | 1M | male |
| Wei Min Hong | Manager of Quality Department | 989.0K | female |
| Zhangyi Hong | Finance Manager | 726.0K | male |
| Sheng Hui Zhou | Audit Office Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4911.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
